Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.

The Phase 2-3, multi-center, randomized, double-blind, placebo-controlled and international study will evaluate the efficacy and safety of inhaled, human AAT in alpha-1 deficient patients with emphysema. The trial will be conducted across several European countries. The study protocol has been designed in agreement with the EMEA under the product's orphan drug designation status.

David Tsur, Chief Executive Officer of Kamada said, “We are very pleased with the advancement of the trial and hope that the rate of enrollment would reflect the excitement of the patients of this potential new treatment. We recognize the importance of bringing this product to this unique patient population for whom, at the moment, there is no therapeutic resolution.




  1. Rainer stahlberg, PhD Rainer stahlberg, PhD United States says:

    Wonderful breakthrough that could be much safer than the current infusion therapy using unpurified  blood plasma. This gives hope to thousands that currently have few options to stop the decline of their lung function.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Impact of COVID-19 vaccination on anti-nucleocapsid antibody levels